No, they're not selling disco balls—but DISCO Pharmaceuticals certainly knows how to shine in biotech. The company name immediately conjures images of glittering mirror balls and 1970s dance floors, an association the founders clearly embraced given their playful branding. Yet the name carries deeper meaning rooted in

Repayment caps have emerged as the defining structural element of synthetic royalty transactions, appearing in 72% of deals from 2019–2024. By 2024, a significant majority of deals included some cap on investor returns, making this a standard feature for development-stage financings. This guide provides comprehensive coverage of cap

The commercialization of academic research has become one of the most consequential—yet least understood—dynamics in global pharmaceutical markets. In 2024, UK university spinouts raised a record £2.6 billion, up 38% from the prior year, even as the broader British high-growth company market contracted by 19%. Across

European biopharma companies frequently monetize their U.S. royalty streams by selling them to American investors. In theory, these royalty financing rights could be sold to European investment funds — yet in practice this remains uncommon.

The first full week of 2026 delivered an unusually dense news cycle. Billion-dollar acquisitions, major licensing partnerships, the year's first biotech IPO, and the FDA's sweeping deregulation of wellness AI at CES 2026 combined to produce one of the more new dense weeks.

A comprehensive analysis of AI-powered healthcare innovations, regulatory shifts, strategic partnerships, and emerging technologies reshaping medicine and wellness

CPP Investments has deployed over $4 billion in life sciences since 2017—from Keytruda royalties to BridgeBio synthetics to biotech venture. How Canada's largest pension fund built a pharma powerhouse through patient capital and creative deal structures.

Introduction and Company Overview Founded in 1998, Gan & Lee Pharmaceuticals (SHSE: 603087) is a Chinese biopharma company specializing in insulin analogues and related medical devices. Headquartered in Beijing with an industrial park of ~200,000 m², Gan & Lee has grown to over 5,500 employees globally. The company

Taiwan's biotech industry reached record output in 2025 as the island leverages semiconductor-era manufacturing expertise to build Asia's next pharmaceutical hub. This analysis examines the companies, regulatory frameworks, CDMO expansion, and investment ecosystem shaping the sector's trajectory.

Pharmaceutical mergers and acquisitions face unprecedented antitrust scrutiny in the United States and European Union. Regulators no longer focus solely on obvious horizontal overlaps where merging firms sell competing drugs but also examine vertical foreclosure risks and pipeline competition—overlaps between marketed drugs and another company's pipeline candidates,